Product image of Paracalcitolo Teva Italia (Paricalcitol) supplied by GNH India

Paracalcitolo Teva Italia

Active Ingredient:
Paricalcitol
Origin:
EU

Paracalcitolo Teva Italia (Paricalcitol)

Paricalcitol, the active ingredient in Paracalcitolo Teva Italia, is a vitamin D analog presented as a oral formulation for renal‑related calcium management use. It is employed primarily in patients with chronic kidney disease to control secondary hyperparathyroidism.

GNH India supplies Paracalcitolo Teva Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Manufacturer / TM Owner

Teva Italia S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Paricalcitol is used within the management of disorders that affect calcium and phosphate metabolism, particularly in chronic kidney disease contexts.

  • Secondary hyperparathyroidism: Helps reduce elevated parathyroid hormone levels in patients on dialysis.
  • Hypercalcemia prevention: Assists in controlling calcium levels when vitamin D therapy is required.
  • Renal osteodystrophy: Contributes to better bone mineral balance in chronic kidney disease patients.

How It Works

  • Paricalcitol binds selectively to the vitamin D receptor (VDR) in renal and parathyroid tissues, modulating gene transcription that lowers parathyroid hormone synthesis and secretion while enhancing calcium absorption without markedly raising serum calcium or phyl­phyl phosphate.

Side Effects

Paricalcitol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

  • Nausea: mild gastrointestinal discomfort.
  • Vomiting: occasional episodes of stomach upset.
  • Diarrhea: loose stools occurring intermittently.
  • Headache: mild to moderate head pain.
  • Fatigue: general feeling of tiredness.
  • Hypercalcemia: mild elevation of blood calcium levels.

Serious or Rare Side Effects

  • Severe hypercalcemia: marked increase in serum calcium requiring medical intervention.
  • Hyperphosphatemia: significant rise in phosphate levels.
  • Allergic reaction: rash, itching, or swelling indicative of hypersensitivity.
  • Acute kidney injury: sudden decline in renal function.
  • Cardiac arrhythmia: irregular heart rhythm linked to electrolyte disturbances.

Precautions & Warnings

Paricalcitol should be used with careful clinical monitoring and adherence to prescribing information.

  • Monitor calcium and phosphate: regular blood tests are required to track mineral levels.
  • Adjust dose in renal impairment: dosing may need modification based on kidney function.
  • Avoid in uncontrolled hypercalcemia: the drug can exacerbate high calcium levels.
  • Caution in pregnancy: limited data; use only if potential benefit outweighs risk.
  • Review concomitant vitamin D therapy: assess total vitamin D exposure.
  • Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Paricalcitol can interact with several medicines that influence calcium, phosphate or vitamin D metabolism.

Major Interactions (Avoid)

  • Calcium supplements: may cause excessive calcium accumulation.
  • High‑dose vitamin D analogues: increase risk of hypercalcemia.
  • Thiazide diuretics: can raise serum calcium levels.

Moderate Interactions (Monitor Closely)

  • Phosphate binders: may alter absorption of paricalcitol.
  • Corticosteroids: can affect calcium balance and bone metabolism.
  • Antifungal azoles (e.g., ketoconazole): may interfere with vitamin D metabolism.

Frequently Asked Questions

Paracalcitolo Teva Italia contains paricalcitol, a vitamin D analog that is prescribed to manage secondary hyperparathyroidism in patients with chronic kidney disease, especially those receiving dialysis. It helps lower elevated parathyroid hormone levels and supports calcium‑phosphate balance.

Paricalcitol selectively activates the vitamin D receptor in the parathyroid glands and kidney cells. This activation modifies gene expression, reducing the synthesis and release of parathyroid hormone while modestly enhancing calcium absorption, thereby helping to control mineral disturbances associated with kidney disease.

The dose of paricalcitol is individualized by the prescribing clinician based on the patient’s laboratory values, dialysis schedule and overall clinical condition. Physicians determine the appropriate strength and frequency according to current treatment guidelines.

Safety data for paricalcitol in pregnancy are limited, and the drug should only be used if the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as it is unclear whether the medication passes into breast milk in significant amounts.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Paricalcitol is designed to suppress parathyroid hormone with a lower propensity to raise serum calcium and phosphate compared with older analogs such as calcitriol. This profile can reduce the risk of hypercalcemia, making it a preferred option for many dialysis patients, though individual response varies.

Store the product at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the tablet’s potency throughout its shelf life.

Paracalcitolo Teva Italia is taken orally, usually once daily or as directed by the prescribing clinician. The tablet should be swallowed whole with water and not crushed or chewed unless specifically instructed.

The most serious adverse events include severe hypercalcemia, hyperphosphatemia, acute kidney injury and rare allergic reactions. Prompt medical evaluation is required if symptoms such as muscle weakness, irregular heartbeat, severe nausea or rash develop.

Paricalcitol is contraindicated in patients with uncontrolled hypercalcemia, known hypersensitivity to the drug, or those receiving high‑dose vitamin D preparations that could cause dangerous calcium elevations. Clinicians should also exercise caution in pregnant women and individuals with severe renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Paricalcitol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT